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Graphical abstract: 
 
Abstract: 
Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the lungs 
to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary disease 
(COPD). Spray drying conditions were optimized to prepare inhalable dry powders, from 
meloxicam aqueous solution with pH adjustment. A comparison study between non-porous and 
large porous particles (LPPs) was carried out to demonstrate the relevance of the aimed large 
size (>5 µm) and low density (<0.2 mg/cm3) formulations. With the appropriate amount of 
porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic diameter and a 
higher deposited fraction than smaller but dense particles. The aerodynamic evaluation of LPPs 
showed that the fine particle fraction (FPF) reached up to 65.8%, while the emitted fraction 
(EF) reached 85.4%, both higher than for the non-porous particles. Stability tests demonstrated 
that, after 10 weeks of storage, no significant difference could be detected in the aerodynamic 
behaviour of the formulations. To the best of our knowledge this is the first time large porous 
particles, with enhanced aerodynamic properties, from an aqueous solution of meloxicam are 
reported. 
Footnote 
AB – Ammonium Bicarbonate 
API – Active Pharmaceutical Ingredient 
CF – Cystic Fibrosis 
COPD – Chronic Obstructive Pulmonary Disease 
D[0.5] – Median Geometric Diameter 
DPI – Dry Powder Inhaler 
EF – Emitted Fraction 
FPF – Fine Particle Fraction 
HA – Sodium Hyaluronate 
LEU – L-Leucine 
LPPs – Large Porous Particles 
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MMAD – Mass Median Aerodynamic Diameter 
MX – Meloxicam 
NSAID – Non Steroidal Anti-Inflammatory Drug 
SD – Spray Dried 
  
4 
 
1 Introduction 
In the past decades, carrier-free dry powder inhalers (DPIs) have shown promises for the local 
pulmonary treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis 
(CF). In carrier-free formulations, active pharmaceutical ingredients (APIs) and excipients are 
formulated together into the inhalable DPI form without using large carriers such as lactose 
(Hoppentocht et al., 2014). 
For pulmonary disorders with increased inflammation, the use of non-steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, gained the attention of research 
studies (Szabó-Révész, 2018). Among NSAIDs, meloxicam (MX) is a low water-soluble 
cyclooxygenase enzyme-2 selective inhibitor, which has anti-inflammatory and antioxidant 
effects. Due to these effects, MX could be of interest for pulmonary administration to locally 
treat CF, COPD or any other lung inflammation (Tsubouchi et al., 2000; Arafa et al., 2007). 
So far, literature data reported preparation of MX containing inhalable microparticles by pre-
suspension spray drying method. Pomázi et al. described the preparation MX particles 
suspended in an aqueous solution of excipients (mannitol, poly-vinyl-alcohol, 
polyvinylpyrrolidone and leucine) which was then spray dried at 130 °C to produce inhalable 
microparticles with enhanced aerodynamic properties (Pomázi et. al., 2011; Pomázi et al, 2013; 
Pomázi et al, 2014). Due to the preparation method, MX was in crystalline form in the 
formulations. Another option for the inhalable microcomposite preparation is the use of MX 
potassium salt form and additional excipients (Poly-vinyl alcohol, leucine) (Chvatal et al, 
2017). Due to the water solubility of the MX salt (Mezei et al., 2009), an easier feed stock 
preparation and spray drying conditions could be developed, leading to amorphous MX 
(Chvatal et al., 2017). 
The newest DPI researches report about several high potency carrier-free formulations prepared 
by spray drying. Co-spray drying has been widely used in the DPI production because it is 
scalable and offers an easily controlled particle formulation. Besides using this process for the 
micronization of the API, it can also lead to good aerodynamic properties for products (Healy 
et al., 2014). Innovative formulations by spray drying can be produced to create special 
structure (e.g. porous particles) and appropriate morphology of the API both for carrier-based 
and for carrier-free formulations (Tsapis, 2014). 
Carrier-free formulation aimed to reduce the intrinsic cohesion of the particles, increase 
dispersion and delivery from the inhaler. Special excipients are used (for e.g. amino acids, 
polymers, bulking agents, phospholipids) in the particle design phase to implement also low 
density and enhanced aerosolization of the particles (Healy et al., 2014). 
Among widely used excipients to increase the aerosolization behaviour of the particles are 
leucine (LEU) and its analogues such as tri-Leucine (Lechuga-Ballesteros et al, 2008; Vehring, 
2008). LEU was shown to promote good aerosolization of the particles by decreasing the 
surface energy (cohesive and adhesive forces) between particles as it is accumulates at particle 
surface (Raula et al., 2010). It was also demonstrated that the LEU (above 20%, w/w content) 
may recrystallizes during the spray drying covering the surface of the particle and protecting it 
against moisture (Li et al., 2016). 
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Biodegradable polymers, such as sodium hyaluronate (HA), are also used to enhance the 
aerosolization of the API. HA can be used in the pulmonary drug delivery as a drug targeting, 
due to its mucoadhesive characteristics, absorption promoter and structure stabilizing effect 
(Martinelli et al., 2017). HA also increases the viscosity of the primary solution to obtain large 
droplets for spray drying and thus larger particle sizes. 
The aerodynamic performance of the DPIs also depends on the density of the powder. Particles 
with low density have better flowability and can be delivered to the lung easier with higher 
deposition (Bosquillon et al., 2001). An exact density value is not clearly established, but most 
of the studies consider the DPI ”low density” from a tap density around 0.4-0.1 g/cm3 or lower 
(Ogienko et al., 2017; Ógáin et al., 2011; Watts et al., 2013). Large porous particles (LPPs) can 
be obtained using porogen agents (e.g. volatile liquids, ammonium carbonate or bicarbonate) 
in the primary solutions or emulsions (Gervelas et al., 2007). The porogen evaporates quicker 
than the dispersion phase is drying, leaving holes in the interior of the larger sized particles 
(N’Guessan et al., 2018; Pham et al., 2013). The formulation of stable structured LPPs with 
the appropriate excipient-API concentration and production properties may be the challenge of 
the pharmaceutical technology.  
We aimed to produce LPPs from MX aqueous solution by forming an MX salt at high pH. For 
this, we have optimized the spray drying procedure, by varying the solution excipient 
concentration. The planned LPPs with particle size larger than 5 µm and tap density lower than 
0.25 g/cm3 should be endowed with enhanced aerosolization properties (Cruz et al., 2011). The 
efficacies of the prepared LPPs were compared with non-porous formulations by their spray 
drying yield, physical chemical properties, morphology and in vitro aerodynamic behaviour. 
To the best of our knowledge, no other studies on the formulation of inhalable LPPs containing 
MX from solution exist. 
2 Materials and methods 
2.1 Materials 
Meloxicam (MX) was obtained from Egis Plc (Hungary). L-Leucine (LEU) and ammonium 
bicarbonate (AB) were purchased from Sigma-Aldrich (France) and sodium hyaluronate (HA) 
from Acros Organics (Belgium). Sodium hydroxide was obtained from Sigma-Aldrich 
(France). Water was purified using a RIOS/MilliQ system from Millipore (France). 
2.2 Preparation of the spray dried microparticles 
MX exhibits a pH dependent solubility: in buffers at pH 7.4-7.7 MX demonstrates almost 43 
fold solubility (1.74±0.2 mg/mL, 37 °C) at this pH than in distilled water (0.04±0.01 mg/mL, 
37 °C) (Horváth et al, 2016). Due to this characteristic, MX was dissolved at room temperature 
(18-20 °C) at higher pH, stabilized with 1 M sodium hydroxide aqueous solution, to prepare a 
stock solution for the spray drying. First, MX was dissolved in the high pH water (8.00±0.1 pH, 
stirring for 2 hours, 600 rpm) at a constant concentration of 1.5 mg/mL for each formulation. 
Secondly, in the MX solution, LEU was dissolved (15 min, 600 rpm) to reach a final 
concentration of 0.75 mg/mL. In some cases, HA was added to finally yield a HA concentration 
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of 0.15, 0.30 or 0.45 mg/mL (HA solutions were prepared the day before spray drying, stirring 
for 24 hours, 400 rpm). These solutions containing MX, MX+LEU or MX+LEU+HA were used 
for the formulation of non-porous particles. For LPP formulations, different concentrations of 
AB were added (0.5, 1.5 and 2.0 mg/mL) which functions as porogen agent as it decomposes 
into CO2 and H2O upon heating. AB was dissolved 5 min before the spray drying (stirring for 
2 min, 200 rpm) to minimize its decomposition prior to spray drying. The inhalable 
microparticles were produced by spray drying using a Büchi B-290 spray dryer equipped with 
a 0.7 mm two-fluid nozzle (Büchi, Switzerland). Drying properties were the followings: 200 
°C inlet temperature, 9 mL/min feed pump rate (30%), 100% aspirator rate, and 414 L/h gas 
flow rate. 
The spray drying yield was calculated as a percentage by dividing the mass of the powder 
collected from the container by the initial mass of solids in the solution prepared for drying. 
Prepared powders were stored in desiccator containing cobalt crystals to decrease moisture 
uptake (at 23±1 °C). 
2.3 Identification of spray dried API 
To investigate the characteristics of the API in the formulations, Raman spectroscopy was 
applied using Thermo Fisher DXR Dispersive Raman with CCD camera (Thermo Fisher Sco. 
Inc., Waltham, MA, USA). Following parameters were used during measurements: laser diode 
operating at a wavelength of 780 nm; the applied laser power was 6-24 mW at 25 µm slit 
aperture size on a 2 µm spot size; spectra were collected with 6 sec exposure time of 20 scanning 
in the spectral range of 3300-200 cm-1. Reference sample, MX-recrystallized, was obtained with 
dissolving MX with the same method as MX solutions were prepared for spray drying. 1.5 
mg/mL MX was dissolved in 8±0.1 pH sodium hydroxide aqueous solution (stirring for 2 hours, 
600 rpm) and dried out at 40 °C, for 24 hours to study the changes during dissolution. 
The actual API content (%) after spray drying was measured by dissolving 1.0-1.1 mg 
formulation in 25 ml of methanol:pH 7.4 phosphate buffer (60:40%, v/v), which solution was 
used for the aerodynamic assessment also. Solutions were mixed for 10 min, 600 rpm and API 
content was quantified by UV/Vis spectrophotometry (ATI-UNICAM UV/VIS 
Spectrophotometer, Cambridge, UK) at 362 nm wavelength. Each sample was measured in 
triplicate. The calibration curve y= 0.00465x, R2=0.9994 was used for quantification. Values 
LOD (0.037 µg/mL) and LOQ (0.124 µg/mL) were also established. 
2.4 Morphology 
Scanning electron microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) 
was used to characterize the morphology of the spray dried formulations, applying 10 kV high 
voltage and 1.3-13.0 mPa air pressure. A high vacuum evaporator and argon atmosphere was 
used to sputter-coat samples with gold-palladium in order to make them conductive (Bio-Rad 
SC 502, VG Microtech, Uckfield, UK). 
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2.5 Particle size distribution 
The geometric diameter of the particles was established using laser diffraction (Mastersizer 
2000 equipped with a Sirocco dry disperser, Malvern Instruments, France). For the 
measurements a micro size plate was used at a dispersing pressure of 2 bars. Each sample was 
measured in triplicate. The particle size distribution was characterized by the D[0.1] (10% of 
the volume distribution is below this value), D[0.5] (the volume median diameter is the diameter 
where 50% of the distribution is above and 50% is below) and D[0.9] (90% of the volume 
distribution is below this value) values. The size distribution Span was calculated according to 
Eq. 1. A high Span value denotes a broad particle size distribution. The higher the Span value, 
the broader the particle size distribution is (Li et al., 2004). All samples were measured in 
triplicate. 
 (Eq. 1) 
2.6 Density measurements 
The density of the formulations was measured using a 5 mL cylinder, filled with 2-4 mL powder 
(for bulk density) and tapped 1000 times (for tap density) using a tapping apparatus (Pharma 
test PT-TD1) (European Pharmacopeia 9th edition). All samples were measured in triplicate. 
2.7 Structural analyses 
To establish the crystalline or amorphous character of the spray dried samples, X-ray powder 
diffraction (XRPD) spectra were recorded with a BRUKER D8 Advance X-ray diffractometer 
(Bruker AXS GmbH, Karlsruhe, Germany) system with Cu Kα1 radiation (λ = 1.5406 Å) over 
the interval 3-40°. Measurement conditions were as follows: target, Cu; filter, Ni; voltage, 40 
kV; current, 40 mA; time constant, 0.1 s; angular step 0.010°. 
2.8 Aerodynamic assessment 
The aerosolization efficacy of the spray dried formulations was assessed in vitro, using an 
Andersen cascade impactor - Apparatus D, (European Pharmacopeia 9th edition), Copley 
Scientific, Switzerland). The inhalation flow rate was set at 30±1 L/min (High-capacity Pump 
Model HCP5, Critical Flow Controller Model TPK, Copley Scientific Ltd., Nottingham, UK). 
The inhalation time was 4 s for one inhalation simulation. Breezhaler® single dose devices 
were used, with size 3 capsules (transparent, Capsugel) filled with 2-2.5 mg of powder 
(constantly for each formulation). The inhaler was actuated twice for each capsule. The plates 
of the impactor were coated with 1 % w/v mixture of Span 85 and cyclohexane, to allow for the 
attachment of floating particles. After actuation, the inhalation device, the capsules, the 
induction port, the collection plates and the filter were washed with methanol:pH 7.4 phosphate 
buffer (60:40 %, v/v) to collect and dissolve the deposited API. The collected MX was 
quantified by UV/Vis spectrophotometry (ATI-UNICAM UV/VIS Spectrophotometer, 
Cambridge, UK) at 362 nm wavelengths. 
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Aerodynamic properties (Fine particle fraction – FPF and Mass median aerodynamic diameter 
– MMAD) were calculated from a plot of the cumulative percentage undersize of API on log 
probability scale against the effective cut-off aerodynamic diameter (Colombo et al., 2012). 
The emitted fraction (EF) was expressed as the percentage of the API found in the cascade 
impactor (except the API found in the capsules and device) after inhalation relative to the total 
loaded dose. 
All the samples were measured at the 1st week after the spray drying and after 10 weeks of 
storage. Samples were stored at room temperature (23±1 °C), in a separate desiccator containing 
cobalt crystals to assess for their stability. Each sample was measured in triplicate. Statistical 
analyses were taken for the stability assessment using t-test calculation, 0.05 significance level 
and one-tailed hypothesis. 
3 Results and discussion 
Formulations were prepared according to Table I, by fixing MX concentration and varying the 
content in LEU and HA. In addition, non-porous particles (no AB added) were compared to 
LPPs prepared with AB. 
Table I. Composition of the solutions prepared for spray drying (mg/mL) and the compositions 
of the spray dried products (%). MX=meloxicam, LEU=leucine, HA=sodium hyaluronate and 
AB=ammonium bicarbonate. 
Sample names MX LEU HA AB* 
Non-porous particles 
MX-SD 1.5 mg/mL (100%) - - - 
MX/LEU 1.5 mg/mL (66.7%) 
0.75 mg/mL 
(33.3%) - - 
MX/LEU/HA0.3 1.5 mg/mL (58.8%) 
0.75 mg/mL 
(29.4%) 
0.30 mg/mL 
(11.8%) - 
MX/LEU/HA0.15 1.5 mg/mL (62.5%) 
0.75 mg/mL 
(31.2%) 
0.15 mg/mL 
(6.3%) - 
Large porous particles 
MX/LEU/HA0.3/AB1.5 1.5 mg/mL (58.8%) 
0.75 mg/mL 
(29.4%) 
0.30 mg/mL 
(11.8%) 1.5 
MX/LEU/HA0.15/AB1.5 1.5 mg/mL (62.5%) 
0.75 mg/mL 
(31.2%) 
0.15 mg/mL 
(6.3%) 1.5 
MX/LEU/HA0.3/AB2 1.5 mg/mL (58.8%) 
0.75 mg/mL 
(29.4%) 
0.30 mg/mL 
(11.8%) 2.0 
MX/LEU/HA0.15/AB2 1.5 mg/mL (62.5%) 
0.75 mg/mL 
(31.2%) 
0.15 mg/mL 
(6.3%) 2.0 
*AB is not present in the dried samples as it decomposes into CO2 and H2O during spray drying.
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3.1 Identification of API and drug content in the spray dried formulations  
 
Fig. 1. Raman spectra of the raw MX (MX-raw), MX dissolved in sodium hydroxide at 1.5 
mg/mL and dried out at 40 °C, 24 hours (MX-recrystallized) and spray dried MX (MX-SD). 
The Raman spectrum of MX-raw exhibits characteristic bands at 1155, 1309, 1540 and 1595 
cm-1 (Fig. 1.). MX-recrystallized shows difference at the 1390 cm-1 compared to MX-raw where 
this band is missing. However, there is no difference in the spectra of the spray dried and the 
recrystallized samples. These Raman spectra are similar to the spectra of MX sodium salt 
according to Bio-Rad Laboratories database (Bio-Rad Laboratories, Inc. SpectraBase; 
Meloxicam sodium). Based on this result it was established that during dissolution of MX (at 
pH 8±0.1 in sodium hydroxide aqueous solution) MX sodium salt form was obtained. 
 
Fig. 2. Comparison of the Raman spectra of the spray dried MX (MX-SD) and one of the LPP 
formulations (MX/LEU/HA0.3/AB2). 
Spray dried MX (MX-SD) and formulations with excipients (Fig. 2. MX/LEU/HA0.3/AB2 LPP 
formulation presented) exhibit the same spectra as MX sodium salt with characteristic Raman 
bands at 1390 and 1595 cm-1, indicating MX sodium salt form is present in spray dried 
formulations. 
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3.2 Particle morphology 
 
Fig. 3. Scanning Electron Microscopy pictures of the non-porous particles (A: MX-SD, B: 
MX/LEU, C: MX/LEU/HA0.3, D: MX/LEU/HA0.15) and large porous particles (E: 
MX/LEU/HA0.15/AB1.5, F: MX/LEU/HA0.15/AB2, G: MX/LEU/HA0.3/AB1.5, H: 
MX/LEU/HA0.3/AB2). 
From the SEM pictures, one can observe that the excipient free sample (A: MX-SD) exhibits a 
slightly rough surface and spherical-like shape (Fig. 3.). The same surface morphology was 
obtained with the spray drying of meloxicam potassium salt from aqueous solution (Chvatal et 
al., 2017). In other studies, the spray drying of meloxicam from aqueous suspension resulted in 
smooth surface particles with around 19 µm size (Pomázi et al, 2011). The presence of LEU 
increased the roughness of the surface and resulted in irregular-shaped particles (B: MX/LEU, 
C: MX/LEU/HA0.3, D: MX/LEU/HA0.15). The shape modification can be explained by the 
crystallization of LEU on droplet surface forming an external shell which collapses during the 
spray drying process (Vehring, 2008). The surface accumulation of LEU and the resulting rough 
surface may reduce the adhesion between particles and the attachment to capsule or inhalation 
device walls, leading to higher EF or FPF values (Aquino et al, 2012; Mangal et al., 2015). 
With 0.15-0.30 mg/mL HA content (C: MX/LEU/HA0.15 and D: MX/LEU/HA0.3) the particles 
kept similar wrinkled surfaces and the polymer has no visible impact on the morphology. 
However, literature data report that sodium hyaluronate could promote surface roughness of 
spray dried salbutamol sulphate particles (Li et al., 2017). LPPs exhibit significantly different 
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morphology than non-porous formulations proving the essential role of the porogen agent AB. 
The SEM pictures further demonstrated the porogen effect of AB, which was an essential 
excipient for LPP formulation. Samples MX/LEU/HA0.15/AB1.5 (E), MX/LEU/HA0.15/AB2 (F), 
MX/LEU/HA0.3/AB1.5 (G) and MX/LEU/HA0.3/AB2 (H) present spherical shaped large sized 
particles. However the surface roughness of LPPs was much lower, slight wrinkles can be 
detected on the surface of the spherical particles. This change in shape could arise from the gas 
formation from AB during the drying procedure, which blows up the wrinkled structure (Fig. 
3). This effect of AB is a well described in literature (Cruz et al., 2011; Nolan et al., 2009; 
Gervelas et al., 2007). Some of the broken shells demonstrate the internal hollow structure 
which reflects the porosity and low density. 
3.3 Size distribution 
Despite all the powders were prepared using similar drying parameters, the final particle size 
distributions were different (Table II.). The geometric diameter of spray dried MX was around 
3 µm, nearly the same as the sample prepared with LEU (MX-SD 3.2 µm and MX/LEU 3.4 
µm). Incorporating 0.75 mg/mL LEU in the formulation did not increase the geometric size of 
the MX containing particles as reported with other MX formulations using 0.6 g/L or higher 
LEU concentrations (Pham et al, 2013; Chvatal et al, 2017). Studies with different active 
ingredients also showed no effect of leucine concentration on particle size up to 20% w/w 
(Aquino et al, 2012) or only a low effect up to 15% w/w (Mangal et al, 2015). We demonstrated 
that the particle size is slightly increasing with an increasing amount of HA: from 3.4 µm up to 
4.3 µm with 0.30 mg/mL HA. In case of LPPs the geometric size was also increased 
significantly with the higher HA concentration (from 5.0 µm to 5.6 µm with 0.15 and 0.30 
mg/mL HA concentrations respectively). This increase probably arises from an increase of the 
viscosity of the spray dried solution leading to larger droplets and thus resulting in larger 
particle size. Li et al. also demonstrated that increased sodium hyaluronate concentration 
increases the particle size of co-spray dried salbutamol sulphate formulations from 3.8 µm up 
to 4.8 µm (0.20 and 0.35% w/w HA concentrations respectively) (Li et al, 2017). With addition 
of AB to the LEU and HA combination, we obtained the aimed larger geometric diameter 
(larger than 4.9 µm) due to the formation of pores (blowing effect) of AB, as AB decomposes 
into water and gas during the drying process (Cruz et al., 2011; Pham et al, 2015). No evident 
effect on the geometric size was detected comparing 1.5 and 2.0 mg/mL AB concentrations. 
Both non-porous particles and LPPs have narrow size distribution with Span ≤2.0. No 
significant differences were detected between the geometric diameter of the particles measured 
at 1st week and 10 weeks after of storage. 
3.4 Density of the spray dried microparticles 
As expected, non-porous particles have higher density than LPPs. Comparing the tap and bulk 
density, it can be established, that the difference between tap and bulk density of LPPs is lower 
than the difference between the same parameters for non-porous particles. This lower tap-bulk 
density differences indicates the better rearrangement of LPPs upon tapping. Briefly, from the 
density of the spray dried MX (MX-SD) and the formulation with 0.75 mg/mL of LEU 
(MX/LEU) it is clear that the presence of LEU increased the tap density from 0.36 up to 0.45 
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g/cm3 (Table II.). However, the bulk densities of these two formulations were similar (0.23 and 
0.27 g/cm3). This can be explained with the rough surface LEU-containing particles: particles 
with rough surface or wrinkled shape can pack more efficiently and result in higher tap density 
(Simon et al., 2016). Our results were similar with previous observations where leucine 
inclusion up to 15% (w/w) led to higher bulk density powders while up to 20% (w/w) produced 
powders with similar or slightly lower bulk density (Aquino et al, 2012). Results show that the 
HA content has no relevant influence on the density of the powders. Despite the fact that HA is 
increasing the viscosity of solutions, it has no significant effect on the density of dried particles. 
Without AB all the samples containing HA (MX/LEU/HA0.15 and MX/LEU/HA0.3) had a tap 
density around 0.42-0.47 g/cm3. Low density of LPPs is related to the AB content which leads 
to the formation of a porous structure as it decomposes upon drying. The 2.0 and 1.5 mg/mL 
AB content have almost the same density decreasing effect and all the following samples 
(MX/LEU/HA0.15/AB1.5, MX/LEU/HA0.15/AB2, MX/LEU/HA0.3/AB1.5 and 
MX/LEU/HA0.15/AB2) reach tap density <0.19 g/cm3. 
 
  
Table II. Compositions of the non-porous and large porous particles, prepared with the optimized spray drying conditions (200 °C inlet 
temperature, 100% aspirator capacity, 9 mL/min feed pump rate, and 414 L/h gas flow rate), the spray drying characteristics (API content and 
spray drying yield), size distribution (D[0.5] = Median geometric diameter and Span) and density properties (bulk and tap density). Data are 
represented as mean ±S.D., n=3. 
Sample names Spray drying yield (%) 
Final API 
content (%) D[0.5] (µm) Span Bulk density (g/cm3) 
Tap density 
(g/cm3) 
Non-porous particles 
MX-SD 88±2.76 89.7±1.3 3.2±0.08 1.4±0.08 0.23±0.02 0.36±0.06 
MX/LEU 84±2.25 67.1±1.1 3.4±0.02 1.5±0.01 0.27±0.01 0.45±0.05 
MX/LEU/HA0.3 59±5.49 57.2±0.2 4.3±0.01  1.7±0.11 0.28±0.01 0.47±0.03 
MX/LEU/HA0.15 64±6.62 62.0±0.3 3.9±1.07 1.7±0.03 0.27±0.01 0.42±0.10 
Large porous particles 
MX/LEU/HA0.3/AB1.5 62±2.13 53.6±2.1 5.6±0.73 2.0±0.10 0.09±0.01 0.14±0.01 
MX/LEU/HA0.15/AB1.5 67±2.39 55.3±0.3 5.0±0.60 1.9±0.22 0.09±0.01 0.15±0.01 
MX/LEU/HA0.3/AB2 62±2.07 50.7±1.0 5.6±0.64 2.0±0.13 0.07±0.02 0.10±0.02 
MX/LEU/HA0.15/AB2 68±3.75 58.7±1.6 4.9±0.60 1.9±0.31 0.10±0.02 0.19±0.05 
 
 3.5 Structural analyses 
 
Fig. 4. XRPD spectra: The crystalline raw MX (MX-raw), and LEU (LEU-raw) are compared 
with the spray dried sample (A), non-porous particles (B: MX/LEU, C: MX/LEU/HA0.3, D: 
MX/LEU/HA0.15) and LPPs (E: MX/LEU/HA0.3/AB1.5, F: MX/LEU/HA0.15/AB2, G: 
MX/LEU/HA0.15/AB1.5, H: MX/LEU/HA0.3/AB2). 
X-Ray powder diffraction was then used to characterize the crystalline state of MX after the 
spray drying process (Fig. 4.). The raw MX has characteristic peaks with the highest intensities 
at 6.6°, 11.4°, 13.1º, 13.5°, 15.1º, 18.7°, 19.3°, 25.9° and 26.4º 2-theta peaks indicating its 
crystalline structure (Aytekin et al., 2018). The fact that the characteristic peaks of crystalline 
MX are missing from the diffractogram of the spray dried sample (MX-SD) indicates that the 
raw material becomes amorphous when spray drying without excipients (Fig. 4. and 
Supplementary material S1). However, characteristic peaks of MX at 6.6°, 11.4°, 13°, 13.6° 
and 19.2° 2-theta appear in the formulations containing LEU (Supplementary Material S1), 
indicating a low level of crystallinity. We detected the same characteristic peaks of LEU that 
literature data reported (Najafabadi et al., 2004; Li et al., 20016; Chvatal et al., 2017). The 
characteristic peak 5.9° 2-theta of LEU could be observed on the spectra of the formulations 
but broader and with much lower intensity. These low intensity peaks demonstrate the low 
crystallinity of LEU after spray drying. The presence of HA has no effect on the diffractogram 
of the samples. 
3.6 Aerodynamic properties 
The aerodynamic properties (EF, FPF and MMAD) of powders were tested at 1st week and 10 
weeks after the spray drying. No significant difference can be detected in the EF, FPF and 
 MMAD of the samples comparing the properties at 1st week and after 10 weeks storage 
(desiccator, 23±1 °C). The aerodynamic properties of the spray dried formulations remain 
unchanged.  
An effect of excipients was observed for the non-porous formulations: those prepared with LEU 
have significantly higher EF than MX-SD. LEU increases the EF from ≤53.6% to ≥57.1%. LEU 
not just minimized the cohesion between particles, but also reduces the attachment to capsule 
wall during inhalation which resulted in higher EF values (Aquino et al, 2012; Mangal et al., 
2015). However, contrary to other results showing that surface roughness lead to an increased 
FPF for LEU containing corrugated particles (Chew et al, 2005), we did not detect the FPF 
increasing effect of LEU. For the non-porous particles, the FPF remained in the 35-41% range 
independently of the excipients.  
There are significant differences in the aerodynamic properties of LPPs and non-porous 
particles. LPPs result in higher EF and FPF than non-porous formulations (Table III). Briefly, 
the EF of the non-porous particles is not exceeding 62.1%, while LPPs EF are above 76.1% in 
all cases. The high EF of LPPs is related to the good flowability of particles and low adhesion 
to the capsule and device walls. It can be demonstrated, that the used AB concentrations have 
a relevant effect on the aerodynamic behaviour of LPPs. LPPs have significantly lower tap 
density (comparing to non-porous particles) which resulted improved lung deposition (FPF 
54.5-65.8%). Bosquillon et al also established the same correlation between density and 
aerodynamics: the lower the tap density (0.04–0.25 g/cm3), the higher the FPF (Bosquillon et 
al, 2001). LPP formulations prepared with 1.5 mg/mL AB concentrations have lower FPF 
(≤57.4%) than formulations containing 2.0 mg/mL AB (≥59.7%). The increased AB 
concentration (2.0 mg/mL) resulted in the highest FPF with 65.8% in case of 
MX/LEU/HA0.15/AB2 (measured at the 1st week). Despite the significant effect on the FPF, AB 
concentration has no significant effect on the EF of the LPPs. Comparing the LPP formulations, 
it can be concluded that HA content has no significant effect on the EF or FPF. 
  
 Table III. Comparison of the aerodynamic properties of the non-porous and large porous 
particles tested at 1st week and 10 weeks after spray drying simulating a 30 L/min inhalation 
flow rate. EF = emitted fraction, FPF = fine particle fraction. Data are represented as mean 
±S.D., n=3. 
Sample names 1
st
 week 10th week 
EF (%) FPF (%)* EF (%) FPF (%)* 
Non-porous particles 
MX-SD 53.6±10.5 38.6±4.7 50.4±6.7 37.9±4.8 
MX/LEU 61.7±4.1 41.2±3.3 59.9±8.1 39.7±1.7 
MX/LEU/HA0.3 57.1±1.8 36.2±4.2 61.5±3.8 36.8±3.1 
MX/LEU/HA0.15 59.9±1.7 35.6±2.7 62.1±2.9 35.9±2.6 
Large porous particles 
MX/LEU/HA0.3/AB1.5 79.5±4.2 54.5±2.1 79.4±2.3 55.9±2.3 
MX/LEU/HA0.15/AB1.5 77.5±6.8 57.4±5.6 76.1±9.9 54.5±10.1 
MX/LEU/HA0.3/AB2 79.5±5.5 59.7±4.0 85.4±3.2 60.5±1.6 
MX/LEU/HA0.15/AB2 82.8±6.8 65.8±3.2 82.3±8.3 63.0±4.5 
*FPF (<5 µm) was expressed with reference to the loaded dose. 
The presented low density LPPs (≤0.19 g/cm3) have better aerosolization properties (EF≥76.1% 
and FPF≥54.5%) and can reach the lower airways more easily than the smaller but denser non-
porous particles (EF≤62.1% and FPF≤41.2%). Figure 5 demonstrates the relevance of the large 
geometric diameter (>5 µm) and low density (<0.25 g/cm3) LPPs for lung delivery (Fig. 5.). 
LPPs and non-porous particles result in the same MMAD values (average 2.55 µm) with no 
significant differences. However, LPPs have larger geometric diameter (≤4.9 µm) than non-
porous formulations. In case of non-porous formulations the increasing D[0.5] resulted in larger 
MMADs. In case of LPPs the MMAD is not increasing with the D[0.5]. Different effects were 
observed comparing the excipient concentrations just in case of LPPs. LPPs with 2.0 mg/mL 
AB concentration exhibit lower MMAD (2.41-2.32 µm) than those with 1.5 mg/mL (2.57-2.74 
µm). The higher amount of porogen affected positively the flowability of the particles thus 
resulted in lower aerodynamic diameter. By contrast, there is no significant difference between 
the MMAD of 0.15 and 0.30 mg/mL HA concentrations. 
  
Fig. 5. Comparison of the aerodynamic and geometric diameter (MMAD = mass median 
aerodynamic diameter and D[0.5] = median geometric diameter) of the spray dried 
formulations. Data show the low density LPPs (E: MX/LEU/HA0.3/AB1.5, F: 
MX/LEU/HA0.15/AB1.5, G: MX/LEU/HA0.3/AB2 and H: MX/LEU/HA0.15/AB2) have the same 
or smaller MMAD than smaller but denser non-porous particles (A: MX-SD, B: MX/LEU, C: 
MX/LEU/HA0.3 and D: MX/LEU/HA0.15). Data are represented as mean ± S.D., n=3. 
4 Conclusions 
In the present study, two types of carrier-free DPIs were produced and compared: non-porous 
and LPP formulations of MX. We produced inhalable microparticles from MX aqueous solution 
with pH adjustment at pH 8±0.1, to facilitate the particle formulation process with in situ water 
soluble salt formation. Inhalable microparticles were produced with optimized spray drying 
conditions: 200 °C inlet temperature, 100% aspirator rate, 9 mL/min pump rate, and 414 L/h 
gas flow rate. LPPs with particle size larger than 4.9 µm and tap density lower than 0.19 g/cm3 
were obtained using 1.5 mg/mL MX, with 0.75 mg/mL LEU, 0.15 and 0.3 mg/mL HA; 1.5 and 
2.0 mg/mL AB (samples MX/LEU/HA0.3/AB1.5, MX/LEU/HA0.15/AB2, MX/LEU/HA0.15/AB1.5 
and MX/LEU/HA0.3/AB2). The aerosolization efficacies of the prepared LLPs were compared 
with the non-porous particles by testing the in vitro aerodynamical behaviour (with Andersen 
Cascade Impactor). The study was carried out using 30 L/min to simulate the low inhalation 
flow rate characteristic of lung inflammation diseases. LPPs show EF above ≥77.5% and FPF 
above ≥54.5%, both exceeding the non-porous particles values. The aerodynamical properties 
remain unchanged after 10 weeks of storage for all formulations. The concentration of AB, a 
porogen agent used in the primary solutions is a critical parameter of the LPP formulation. The 
best considered LPPs (with the highest spray drying yield ≥62% and FPF reaching 65.8%) were 
the ones containing 2 mg/mL AB as porogen beside the appropriate concentration of LEU and 
HA (samples MX/LEU/HA0.3/AB2 and MX/LEU/HA0.15/AB2). The presented aerodynamic 
properties have no significant difference measured after 1 and 10 weeks of storage. Thanks to 
the good aerosolization properties, the presented LPPs containing MX may offer an effective 
local treatment for lung inflammation diseases and should be tested in vivo in a near future. 
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Figure S1: Zoom on the diffractograms of the spray dried samples (A), non-porous particles (B: 
MX/LEU, C: MX/LEU/HA0.3, D: MX/LEU/HA0.15) and LPPs (E: MX/LEU/HA0.3/AB1.5, F: 
MX/LEU/HA0.15/AB2, G: MX/LEU/HA0.15/AB1.5, H: MX/LEU/HA0.3/AB2). 
 
